A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma
- Conditions
- Hodgkin Disease Lymphoma
- Interventions
- Drug: Investigator's choice of Chemotherapy
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Akeso
- Target Recruit Count
- 60
- Registration Number
- NCT05244642
- Locations
- 🇨🇳
Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳Xiangya Hospital Central South University, Changsha, Hunan, China
🇨🇳Qilu Hospital of Shandong University, Jinan, Shandong, China
A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer
- Conditions
- Locally Advanced Cervical Carcinoma
- Interventions
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Akeso
- Target Recruit Count
- 636
- Registration Number
- NCT05235516
- Locations
- 🇨🇳
Hubei Cancer Hospital, Wuhan, Hubei, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Guizhou Cancer Hospital, Guiyang, Guizhou, China
A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors
- Conditions
- Advanced Malignant Tumors
- Interventions
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2022-08-11
- Lead Sponsor
- Akeso
- Target Recruit Count
- 130
- Registration Number
- NCT05235542
- Locations
- 🇨🇳
Shanghai Renji Hospital, Shanghai, China
A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors
- Conditions
- Advanced Malignant Tumors
- Interventions
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- Akeso
- Target Recruit Count
- 114
- Registration Number
- NCT05229497
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer
- Conditions
- Metastatic Triple-negative Breast CancerLocally Advanced Triple-negative Breast Cancer
- Interventions
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Akeso
- Target Recruit Count
- 120
- Registration Number
- NCT05227664
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, China
🇨🇳Xiangyang Central Hospital, Xiangyang, China
AK104 in Neoadjuvant Treatment of Cervical Cancer
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Akeso
- Target Recruit Count
- 14
- Registration Number
- NCT05227651
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hanzhong, Zhejiang, China
A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer
- Conditions
- Advanced Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Akeso
- Target Recruit Count
- 44
- Registration Number
- NCT05215067
- Locations
- 🇨🇳
Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
A Study of AK112 in Advanced Malignant Tumors
- Conditions
- Advanced Malignant Tumors
- Interventions
- First Posted Date
- 2022-01-28
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Akeso
- Target Recruit Count
- 250
- Registration Number
- NCT05214482
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2022-01-20
- Lead Sponsor
- Akeso
- Target Recruit Count
- 30
- Registration Number
- NCT05200273
- Locations
- 🇦🇺
Ashford Cancer Centre, Kurralta Park, South Australia, Australia
Phase 3 Clinical Study of AK112 for NSCLC Patients
- Conditions
- Non-Squamous Non-small Cell Lung Cancer
- Interventions
- Drug: Placebo Injection
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Akeso
- Target Recruit Count
- 322
- Registration Number
- NCT05184712
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China